Danaher Corporation vs Lufax Holding Ltd — how do they compare? Danaher Corporation trades at $219.52 (market cap $152.87B), while Lufax Holding Ltd trades at $0.99 (market cap $982.89M). The key difference: Danaher Corporation is far larger — about 155.5× Lufax Holding Ltd's market cap, and Danaher Corporation pays a 0.74% dividend while Lufax Holding Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and Lufax Holding Ltd for 13 Days on average.
| DHR | LU | |
|---|---|---|
Market Cap | $152.87B | $982.89M |
Volume | 5,228,698 | 3,323,384 |
Sector | Health | Financials |
52-Week High | $242.05 | $3.93 |
52-Week Low | $161.91 | $0.95 |
Typical Hold Time | 69 Days | 13 Days |
Enterprise Value | $175.08B | $58.81B |
Dividend Yield | 0.74% | — |
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $218.49, up 1.36% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst consensus is strongly bullish with a $230.31 price target, supported by institutional buying activity and a recent dividend announcement.
The outlook for DHR is positive, driven by earnings momentum and institutional confidence, but risks include elevated valuation multiples and competitive pressures in the healthcare sector. Investors should weigh the strong analyst support against potential margin compression and macroeconomic headwinds affecting capital spending.
Lufax (LU) trades at $0.98, showing minimal daily movement with a 0.09% gain. The stock faces significant fundamental challenges with consecutive quarterly losses and declining revenue, though valuation metrics appear deeply discounted with P/S of 0.25 and P/B of 0.07. Recent corporate actions include a 10:1 reverse stock split effective October 2026. Technical indicators show mixed signals with bearish moving averages but bullish oscillators, while analyst sentiment remains predominantly positive despite operational headwinds.
LU presents a high-risk, event-driven opportunity with deep value characteristics but substantial operational challenges. The company's negative profit margins and declining revenue trajectory create significant execution risk, though strong backing from parent company Ping An and potential Hong Kong listing catalysts offer upside potential. Investors should weigh the discounted valuation against persistent profitability concerns and regulatory pressures in China's financial services sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →Lufax Holding Ltd is a leading financial technology (fintech) platform in China. The company operates a technology-driven personal financial services platform that offers a wide range of loans and wealth management products to its users. Lufax primarily serves the rapidly growing wealth and consumption needs of China’s mass affluent and affluent populations through a combination of its digital platform and an extensive offline network.
Read more on LU →